Company intelligence / Profile preview

Delian Capital

Beijing, Beijing Municipality, China

Ownership: Private
Development stage: Other

Overview

Delian Capital is a Beijing-based venture capital/private equity firm specializing in early and growth-stage investments with a strong focus on healthcare, biotechnology, high-end manufacturing, and cutting-edge technologies. The fund has made at least 59–90 investments since its founding in 2011. Its healthcare/biotech portfolio includes notable companies such as HiFiBiO and Amunix Pharmaceuticals. It remains active with recent deals into late-stage rounds like Core Medical’s Series D ($100M) in April 2025.

Therapeutic areas: OncologyInfectious Diseases
Modalities: BiologicMonoclonal antibodySmall moleculeRNA therapy
Industry: Investors

Partnerships

ZhenFundNest.Bio VenturesMorningside Group

Beyond the preview

Go deeper on Delian Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delian Capital.

Explore the full profile